AbbVie Inc. (NYSE:ABBV) went up by 1.63% from its latest closing price compared to the recent 1-year high of $109.15. The company’s stock price has collected 3.42% of gains in the last five trading sessions. Press Release reported on 01/07/21 that Risankizumab (SKYRIZI(R)) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn’s Disease
Is It Worth Investing in AbbVie Inc. (NYSE :ABBV) Right Now?
AbbVie Inc. (NYSE:ABBV) scored a price-to-earnings ratio above its average ratio, recording 23.83 x from its present earnings ratio. Plus, the 36-month beta value for ABBV is at 0.80. Opinions of the stock are interesting as 14 analysts out of 22 who provided ratings for AbbVie Inc. declared the stock was a “buy,” while 2 rated the stock as “overweight,” 6 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $116.90, which is $7.98 above the current price. ABBV currently public float of 1.76B and currently shorts hold a 0.79% ratio of that float. Today, the average trading volume of ABBV was 8.21M shares.
ABBV’s Market Performance
ABBV stocks went up by 3.42% for the week, with a monthly jump of 0.32% and a quarterly performance of 24.31%, while its annual performance rate touched 22.41%. The volatility ratio for the week stands at 2.12% while the volatility levels for the past 30 days are set at 2.04% for AbbVie Inc.. The simple moving average for the period of the last 20 days is 3.83% for ABBV stocks with a simple moving average of 17.53% for the last 200 days.
Analysts’ Opinion of ABBV
Many brokerage firms have already submitted their reports for ABBV stocks, with Bernstein repeating the rating for ABBV by listing it as a “Outperform.” The predicted price for ABBV in the upcoming period, according to Bernstein is $120 based on the research report published on November 10th of the previous year 2020.
Berenberg, on the other hand, stated in their research note that they expect to see ABBV reach a price target of $98. The rating they have provided for ABBV stocks is “Hold” according to the report published on September 29th, 2020.
Atlantic Equities gave a rating of “Overweight” to ABBV, setting the target price at $115 in the report published on June 23rd of the previous year.
ABBV Trading at 7.90% from the 50-Day Moving Average
After a stumble in the market that brought ABBV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.12% of loss for the given period.
Volatility was left at 2.04%, however, over the last 30 days, the volatility rate increased by 2.12%, as shares surge +1.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +35.45% upper at present.
During the last 5 trading sessions, ABBV rose by +3.42%, which changed the moving average for the period of 200-days by +47.66% in comparison to the 20-day moving average, which settled at $105.07. In addition, AbbVie Inc. saw 1.75% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at ABBV starting from Stewart Jeffrey Ryan, who sale 25,290 shares at the price of $105.00 back on Dec 29. After this action, Stewart Jeffrey Ryan now owns 50,969 shares of AbbVie Inc., valued at $2,655,450 using the latest closing price.
RICHMOND TIMOTHY J., the EVP, Chief HR Officer of AbbVie Inc., sale 51,990 shares at $105.00 during a trade that took place back on Nov 27, which means that RICHMOND TIMOTHY J. is holding 0 shares at $5,458,950 based on the most recent closing price.
Stock Fundamentals for ABBV
Current profitability levels for the company are sitting at:
- +41.83 for the present operating margin
- +77.14 for the gross margin
The net margin for AbbVie Inc. stands at +23.57. The total capital return value is set at 30.66, while invested capital returns managed to touch 19.22. Equity return is now at value 203.50, with 6.10 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 4.77, with the company’s debt to enterprise value settled at 0.42. The receivables turnover for the company is 5.89 and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.18.